Chronic Kidney Disease Market: 5 Emerging Therapies to Watch as the Treatment Landscape Expected to Evolve by 2036 | DelveInsight

A diversified late-stage pipeline encompassing endothelin receptor antagonists, aldosterone synthase inhibitors such as lorundrostat, APOL1 inhibitors including MZE829, and cell therapy approaches such as rilparencel is poised to intensify competition, with each modality addressing mechanisms that complement the established SGLT2 inhibitor/MRA backbone. The CKD market expansion is further expected to be supported by rising diagnosis rates, earlier screening based on UACR and eGFR, and broader adoption of combination therapies. 

LAS VEGAS, Sept. 24, 2026 /PRNewswire/ -- Treatment of chronic kidney disease (CKD) focuses on slowing disease progression toward kidney failure, reducing cardiovascular risk, and addressing complications such as anemia and mineral bone disorders. SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRAs), and emerging aldosterone synthase inhibitor combinations are increasingly replacing single-agent RAS blockade, driven by their improved renal and cardiovascular outcomes. Approved therapies in the CKD market include empagliflozin (JARDIANCE) (Boehringer Ingelheim and Eli Lilly), finerenone (KERENDIA) (Bayer), dapagliflozin (FARXIGA/FORXIGA) (AstraZeneca), among others.

Find out more about what is the latest treatment for chronic kidney disease @ https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market

The pharmaceutical companies involved in the emerging pipeline include AstraZeneca (zibotentan/dapagliflozin), Boehringer Ingelheim (vicadrostat + empagliflozin), Mineralys Therapeutics (lorundrostat), ProKidney (rilparencel), Disc Medicine (DISC-0974), and others.

Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that Rilparencel and MZE829 represent potential disease-modifying and precision-genetic opportunities, respectively, with the potential to achieve premium positioning in advanced and APOL1-driven CKD if pivotal data continue to be positive. Thakur further added that DISC-0974 could establish a new anemia-focused revenue segment within the broader CKD market, with limited direct competition from therapies primarily targeting SGLT2i- and MRA-focused mechanisms.

Although SGLT2 inhibitors, non-steroidal MRAs, and RAS blockade have been approved, a significant proportion of CKD patients continue to progress to kidney failure, while the disease remains substantially underdiagnosed. This highlights the need for more effective therapies to slow or halt disease progression, alongside improved strategies for early detection and diagnosis.

Reflecting the growing disease burden and significant unmet medical needs, the chronic kidney disease market across the seven major markets, comprising the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, was valued at approximately USD 5 billion in 2025. The market is projected to expand at a significant CAGR during the forecast period through 2036, driven by the increasing prevalence of CKD, rising awareness and diagnosis, advances in disease management, and the introduction of novel therapies targeting disease progression and associated complications.

Below, we highlight 5 promising emerging therapies poised to reshape the future of the chronic kidney disease market.

AstraZeneca's Zibotentan/Dapagliflozin

Endothelin receptor antagonist/SGLT2 inhibitor

Zibotentan/Dapagliflozin, developed by AstraZeneca, is an investigational oral combination therapy being studied in adults with CKD. The therapy combines zibotentan, an endothelin receptor antagonist, with dapagliflozin, an SGLT2 inhibitor, with the goal of improving kidney outcomes by targeting complementary mechanisms involved in CKD progression. Following encouraging Phase IIb ZENITH-CKD results, which demonstrated up to a 52.5% reduction in urine protein markers, enrollment in the Phase III ZENITH High Proteinuria trial was completed in late 2024, with topline results anticipated in 2027.

Boehringer Ingelheim's Vicadrostat (BI 690517) + Empagliflozin

Aldosterone synthase inhibitor/SGLT2 inhibitor

Vicadrostat + empagliflozin, developed by Boehringer Ingelheim, is an investigational combination therapy being studied in adults with CKD. In a Phase II CKD trial conducted in 2023, the combination demonstrated promising results, with full data showing a significant reduction of up to 39.5% in excessive urinary protein levels (albuminuria) compared with placebo. The vicadrostat and empagliflozin combination may provide a new treatment option for people living with CKD.

Discover more about the chronic kidney disease treatment market @ Chronic Kidney Disease Drugs Market

ProKidney's Rilparencel

Stabilizes eGFR decline

ProKidney is developing rilparencel, an investigational cell therapy product designed to preserve kidney function by stabilizing estimated glomerular filtration rate (eGFR) in patients with advanced CKD. The company is developing rilparencel with the potential to delay or prevent the need for dialysis. Rilparencel is a percutaneous, minimally invasive injectable product prepared from the patient's own kidney cells. As rilparencel is prepared from the patient's own cells, immunosuppressive therapy to prevent rejection is not required. To date, clinical studies suggest that rilparencel treatment in patients with advanced CKD and diabetes may positively impact kidney function by stabilizing eGFR or attenuating the rate of eGFR decline.

Mineralys Therapeutics' Lorundrostat

Aldosterone synthase inhibitor

Lorundrostat, developed by Mineralys Therapeutics, is an investigational oral aldosterone synthase inhibitor being studied in adults with CKD. The therapy selectively inhibits aldosterone production, targeting hormonal pathways implicated in the progression of CKD.

In January 2026, Mineralys Therapeutics provided a corporate update outlining recent and anticipated clinical and regulatory milestones for Lorundrostat in CKD and related conditions. In November 2025, Mineralys Therapeutics reported data on Lorundrostat in CKD and hypertension at ASN Kidney Week 2025, organized by the American Society of Nephrology. In June 2025, Mineralys Therapeutics announced positive topline results from the Phase II EXPLORE-CKD trial evaluating Lorundrostat in patients with CKD and albuminuria.

To know more about what new drug approvals have there been for chronic kidney disease treatment in the US recently, visit @ Chronic Kidney Disease Medications

Disc Medicine's DISC-0974

DISC-0974 is an investigational anti-hemojuvelin (HJV) monoclonal antibody designed to suppress hepcidin production and enhance iron levels for the treatment of anemia of inflammation. DISC-0974 was in-licensed from AbbVie and is being evaluated in multiple clinical studies. Disc completed a Phase 1 clinical study in healthy volunteers and has advanced the program into development for multiple forms of anemia of inflammation. The company has initiated a Phase 1b/2 study in patients with anemia of myelofibrosis (MF) and a Phase 2 study in patients with anemia of inflammatory bowel disease (IBD).

Download the report to understand the top chronic kidney disease drugs manufacturer @ Chronic Kidney Disease Drugs Supplier

Source: Chronic Kidney Disease Market Report 

Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CKD companies, including Boehringer Ingelheim, Eli Lilly, Bayer, AstraZeneca, Mineralys Therapeutics, ProKidney, Maze Therapeutics, Regeneron Pharmaceuticals, Disc Medicine, and others.

Related Reports

Chronic Kidney Disease Clinical Trial Analysis

Chronic Kidney Disease Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CKD companies, including Novo Nordisk, Prokidney, Kibow Pharma, XORTX Therapeutics, Lisata Therapeutics, Unicycive Therapeutics, Novo Nordisk, Bayer, AstraZeneca, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Boehringer Ingelheim, SCOHIA PHARMA, Regeneron Pharmaceuticals, UnicoCell Biomed, OccuRx, Disc Medicine, Shandong Suncadia Medicine, Sarfez Pharmaceuticals, Rege Nephro, Orgenesis, Healx, Benevolent,  and others.

Anemia in Chronic Kidney Disease Market

Anemia in Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key anemia in chronic kidney disease companies, including Jiangsu HengRui Medicine, Shenyang Sunshine Pharmaceutical, Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, Acceleron Pharma, Celgene Corporation, and others.

Moderate and Severe Chronic Kidney Disease Market

Moderate and Severe Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key moderate and severe chronic kidney disease companies, including  Kibow Pharma, Bayer, Roche, Caladrius Biosciences, UnicoCell Biomed, Pharmicell, Scohia Pharma, Unicycive Therapeutics, and others.

End-Stage Renal Disease Market

End-Stage Renal Disease Market Insight, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key ESRD companies, including Medtronic PLC, B. Braun SE, Asahi Kasei Medical Co. Ltd, Cantel Medical (STERIS), Nikkiso Co. Ltd, Nipro Corporation, Fresenius SE & Co. KGaA, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur
info@delveinsight.com 
+14699457679
www.delveinsight.com